Noacid (Pantoprazole Sodium Sesquihydrate)

Pantoprazole, the active ingredient in Noacid, is a proton pump inhibitor presented as an injectable solution for intravenous use. It reduces gastric acid secretion and is employed in the treatment of erosive esophagitis, gastro‑oesophageal reflux disease, acute gastric ulcer bleeding, and Zollinger‑Ellison syndrome.

GNH USA supplies Noacid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Clients include tertiary care centres, transplant units and specialty pharmacies seeking consistent supply of high‑purity injectable medicines.

Pantoprazole is a proton pump inhibitor that reduces gastric acid production, making it useful for several acid‑related gastrointestinal conditions.

- Erosive esophagitis: promotes healing of inflamed esophageal lining by lowering acid exposure. - Gastro‑oesophageal reflux disease (GERD): alleviates heartburn and prevents reflux‑related damage. - Acute gastric ulcer bleeding: stabilises clot formation and reduces re‑bleeding risk by suppressing acid. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion caused by gastrin‑producing tumors.

Pantoprazole administered intravenously may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache: mild pain or pressure sensation in the head. - Diarrhea: loose, watery stools occurring during treatment. - Nausea: feeling of sickness or urge to vomit. - Abdominal pain: discomfort or cramping in the stomach area. - Rash: skin redness or mild eruption.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction with breathing difficulty and hypotension. - Clostridioides difficile infection: severe colitis presenting with profuse diarrhea. - Thrombocytopenia: marked reduction in platelet count leading to bleeding risk. - Elevated liver enzymes: significant increase in ALT/AST indicating hepatic stress. - Stevens‑Johnson syndrome: rare severe skin and mucous membrane disorder.

When using Noacid, clinicians should observe several precautionary measures to ensure patient safety and product integrity. - Assess renal function: adjust or monitor dosing in patients with impaired kidney clearance. - Monitor liver enzymes: periodic testing is advised as hepatic metabolism may be affected. - Use cautiously in the elderly: increased susceptibility to electrolyte disturbances and infections. - Review concomitant medications: avoid or closely watch drugs that require gastric acidity for absorption. - Discontinue if allergic reaction occurs: stop infusion immediately and provide appropriate emergency care. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Pantoprazole can affect the pharmacokinetics of several medicines; awareness of key interactions helps prevent therapeutic failures or toxicity.

Major Interactions (Avoid): - Ketoconazole, itraconazole, posaconazole: reduced antifungal absorption due to increased gastric pH. - Atazanavir and other protease inhibitors: markedly decreased plasma concentrations. - Clopidogrel: diminished activation leading to reduced antiplatelet effect. - Warfarin: potential increase in INR and bleeding risk. - Methotrexate (high dose): impaired renal clearance may raise toxicity.

Moderate Interactions (Monitor Closely): - Digoxin: modest increase in serum levels; monitor for toxicity. - HIV protease inhibitors (e.g., ritonavir): may require dose adjustment. - Oral contraceptives: possible reduction in efficacy; advise backup method. - Diazepam: slight increase in sedation; observe patient response. - Calcium carbonate supplements: may interfere with absorption; separate dosing times.